Vitrolife launches a new series of products within fertility treatment

Vitrolife launches a new series of products within fertility treatment

Vitrolife is launching the G5 Series™, a ground-breaking series of solutions for
in-vitro fertilization. The first presentation is to be made at the European
reproduction congress, ESHRE, that this year is being held in Lyon in France
from July 1-4. Several years' research and development work into embryos' need
for nutrition and protection during assisted reproduction now culminates in the
introduction of the G5 Series™.

The G5 Series™ is based on previous versions of solutions that have been used in
more than 80 countries with very good treatment results. The new products are
the first and only system to have active protection against free oxygen radicals
through the antioxidant lipoate. 

Research has shown that free oxygen radicals can cause so-called oxidative
stress, a process that damages cells and organs. Free oxygen radicals are caused
amongst other things by air and light but are also formed naturally in the body.
Oxidative stress is very negative for the development of the embryo and can
affect the outcome of the treatment. The G5 Series™ counteracts oxidative stress
through the antioxidant lipoate neutralizing free oxygen radicals.

Both preclinical and clinical studies show that the G5 Series™ gives
significantly better embryo development."I am very impressed by the data that have been shown" says Nils Sellbom, Vice
President Marketing and Sales at Vitrolife. "The new G5 Series™ enables us to
offer more clinics a system that gives better results. The new products mean
that the embryo has its nutritional needs satisfied and at the same time it
receives active protection against the stress involved in in-vitro
fertilization."

Historically Vitrolife has found its customers among the more advanced clinics
around the world, but the new G5 Series™ is also particularly suitable for
clinics at a somewhat lower technical level. "We now have access to products
that are also adapted to this commercially important part of the market" says
Nils Sellbom. 

The scientific principles surrounding the G5 Series™ are the subject of a patent
application.



July 2, 2007
Kungsbacka, Sweden 

Magnus Nilsson
CEO



Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced one-time instruments such as needles and
pipettes, for the treatment of human infertility. The Transplantation product
area works with solutions and systems to maintain tissue in optimal condition
outside the body for the required time while waiting for transplantation. The
Stem Cell Cultivation product area works with media and instruments to enable
the use and handling of stem cells for therapeutic purposes. 
     Vitrolife today has approximately 125 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The
Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.